RB 22/2014:Milestone Medical Inc. Receives CE Mark Approval for Epidural Instrument
Firma: MILESTONE MEDICALSpis treści:
1. RAPORT BIEŻĄCY
2. PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ
| Milestone Medical Inc. receives CE Mark Approval for Epidural Instrument<br /> The Board of Directors of Milestone Medical Inc. (WAR: MMD, the “Company”, “Issuer”), today announced that the Company has received CE Mark regulatory approval to market and sell its epidural injection system in Europe. The CompuFlo™ Epidural Computer Controlled Anesthesia System (CompuFlo™ Epidural Model 6000) is intended for the verification of needle tip placement in the lumbar epidural space in patients over age of 18 and the delivery of medication and other fluids in a controlled manner in the lumbar epidural space as part of an in-patient or out-patient procedure established by their Health Care Provider. CE approval for the Issuer’s epidural instrument follows the recent CE approval of the Company’s intra-articular instrument – the Issuer announced receiving CE approval for its intra-articular instrument via EIB report nr 21/2014 published on September 15, 2014. CE approval is an important achievement and further validation of the Issuer’s technology as the Company moves towards commercial sale of the epidural injection system. The Issuer next steps involve securing strategic partners to distribute its products in Europe, as the Company has already done in the U.S. Injection technology has not changed meaningfully since the advent of the hypodermic syringe over 150 years ago. Millions of women who give birth each year choose not to have an epidural due primarily to safety concerns about the high risks associated with this injection. Epidurals represent a multi-billion dollar global market and the Issuer believes its technology can transform these injections from an art to a science. The Company’s injection technology is based on a patented Dynamic Pressure Sensing® system (DPS®), intended to measure the density of body tissue and thus help a clinician know the location of a hypodermic needle during an injection. The system utilizes computer controlled technology to provide real-time feedback to the medical practitioner and identify with precision when a needle has reached the location where a drug should be administered to a patient. It has the added advantage in other applications of controlling the pain that patients typically associate with injections. Legal basis: Section 3.1 of the Exhibit 3 to the Alternative Trading System Rules “Current and Periodical Information in the Alternative Trading System on the NewConnect Market". |
| Data | Imię i Nazwisko | Stanowisko | Podpis | ||
| 2014-09-18 16:35:13 | Leonard Osser | CEO | |||
| 2014-09-18 16:35:13 | Joseph D'Agostino | CFO |
Cena akcji Milestone
Cena akcji Milestone w momencie publikacji komunikatu to 5.15 PLN. Sprawdź ile kosztuje akcja Milestone aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Milestone.
